Info

🌱 來自: Metastatic Colon Cancer

GERCOR

1. Design: Phase III trial, randomized, two sequences: FOLFIRI followed by FOLFOX6 (arm A), and FOLFOX6 followed by FOLFIRI (arm B).
2. Number of patients: 220 (109 in arm A and 111 in arm B).
3. Patient characteristics: Previously untreated patients with assessable metastatic colorectal cancer.
4. Agent:
   • FOLFIRI: folinic acid, FU, and irinotecan.
   • FOLFOX6: folinic acid, FU, and oxaliplatin.
5. Treatment line: First-line and second-line therapy.
6. Trial Name or NCT Number: Not reported.
7. Comparison of two groups:

Outcome	Arm A	Arm B	P value
Median survival	21.5 months	20.6 months	0.99
Median second progression-free survival (PFS)	14.2 months	10.9 months	0.64
First-line therapy response rate (RR)	56%	54%	0.26
First-line therapy median PFS	8.5 months	8.0 months	Not reported
Second-line therapy RR	4%	15%	Not reported
Second-line therapy median PFS	2.5 months	4.2 months	Not reported

Note: The toxicity profiles were different between the two groups, with FOLFIRI causing more frequent mucositis, nausea/vomiting, and alopecia, while FOLFOX6 causing more frequent neutropenia and neurosensory toxicity.